A new bill filed in Florida has proposed the decriminalization of psychedelics, along with the rest of currently illegal drugs, and the promotion of rehabilitation instead of criminalization for drug-related offenses. Democratic Representative Dotie Joseph filed HB 725, titled the “Collateral Consequences of Convictions and Decriminalization of All Drugs Act,” last Tuesday. The bill proposes […]
This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.
The company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease, ALS, and CRPS.
“It’s time for psychedelic medicine to climb down from the ivory tower and into the community,” says Cybin Chief Clinical Officer Dr. Alex Belser.
This study also showed microdosers were less likely to use alcohol and were most likely to abstain from consuming alcohol entirely.
This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.
“We know nothing scientific about psychedelics and people of color and how appropriate our treatments are for people in those communities,” says psychedelic researcher Dr. Monnica Wiliams.
“After adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use,” researchers say.
“People will continue to kill themselves, and my patient will continue to suffer in silence until the Victorian Government allows me to access a new treatment which may finally bring peace to a troubled mind,” says Dr. Eli Kotler.
“Our goal is to provide insight on key parameters that may impact and explain the mechanisms behind low-dose treatments,” says MindMed Executive President Dr. Miri Halperin Wernli.
